Literature DB >> 1716231

Immunohistochemical study of colorectal adenocarcinomas and adenomas with antibodies against carcinoembryonic antigen (CEA), CA19-9, keratin, alpha-tubulin and secretory component (SC).

T Taguchi1, H Kijima, T Mitomi, R Y Osamura.   

Abstract

The immunohistochemical localization of five antibodies against carcinoembryonic antigen (CEA), CA19-9, keratin, alpha-tubulin and secretory component (SC) was investigated in 14 lesions of adenocarcinoma (AC), 22 of adenoma with high-grade atypia (AH), 50 of adenoma with low-grade atypia (AL), and 15 of non-neoplastic mucosa (NNM) of the large intestine. The positive patterns for each staining were divided into three categories (patterns 1, 2, and 3). All neoplastic lesions (AC, AH and AL) were positive for CEA, while 85.7% of AC, 36.4% of AH and 6.0% of AL showed strongly positive staining (pattern 3). 78.6% of AC and 54.5% of AH were positive for CA19-9 in comparison to 20.0% of AL. For keratin, more than 95% of the neoplastic lesions were positive, while 78.6% of AC, 27.3% of AH and 22.0% of AL showed strongly positive staining (pattern 3). For alpha-tubulin, more than 85% of neoplastic lesions were positive, while 50.0% of AC, 36.3% of AH and 26.0% of AL showed strongly positive staining (pattern 3). For SC, in contrast, 42.9% of AC, 27.3% of AH and 8.0% of AL were negative, but 93.3% of NNM were positive. It was concluded that the positive staining rate, especially the rate of pattern 3 for each antibody correlated with the degree of atypia of the colorectal neoplastic lesions (AC, AH and AL).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716231     DOI: 10.1007/bf02781917

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  17 in total

1.  Colorectal carcinoma antigens detected by hybridoma antibodies.

Authors:  H Koprowski; Z Steplewski; K Mitchell; M Herlyn; D Herlyn; P Fuhrer
Journal:  Somatic Cell Genet       Date:  1979-11

2.  Synthesis of secretory component by colonic neoplasms.

Authors:  M E Poger; B R Hirsch; M E Lamm
Journal:  Am J Pathol       Date:  1976-02       Impact factor: 4.307

3.  Aneuploidy and expression of gastric-associated mucus antigens M1 and CEA in colorectal adenomas.

Authors:  H F van den Ingh; J Bara; C J Cornelisse; M Nap
Journal:  Am J Clin Pathol       Date:  1987-02       Impact factor: 2.493

4.  Characterization of monoclonal antibodies to carcinoembryonic antigen with increased tumor specificity.

Authors:  S Jothy; S A Brazinsky; M Chin-A-Loy; A Haggarty; M J Krantz; M Cheung; A Fuks
Journal:  Lab Invest       Date:  1986-01       Impact factor: 5.662

Review 5.  Relationships between immunoglobulins and the intestinal epithelium.

Authors:  W R Brown
Journal:  Gastroenterology       Date:  1978-07       Impact factor: 22.682

6.  Expression of carcinoembryonic antigen, T-antigen, and oncogene products as markers of neoplastic and preneoplastic colonic mucosa.

Authors:  K J McKenzie; D M Purnell; A M Shamsuddin
Journal:  Hum Pathol       Date:  1987-12       Impact factor: 3.466

7.  Immunological heterogeneity of carcinoembryonic antigen: immunohistochemical detection of carcinoembryonic antigen determinants in colonic tumors with monoclonal antibodies.

Authors:  F J Primus; W J Kuhns; D M Goldenberg
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

8.  Immunocytochemical localization of carcinoembryonic antigen in benign and malignant colorectal tissues. Assessment of diagnostic value.

Authors:  M J O'Brien; N Zamcheck; B Burke; S E Kirkham; C A Saravis; L S Gottlieb
Journal:  Am J Clin Pathol       Date:  1981-03       Impact factor: 2.493

9.  Cross-reactivity with normal antigens in commercial anti-CEA sera, used for immunohistology. The need for tissue controls and absorptions.

Authors:  M Nap; K A ten Hoor; G J Fleuren
Journal:  Am J Clin Pathol       Date:  1983-01       Impact factor: 2.493

10.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES.

Authors:  P GOLD; S O FREEDMAN
Journal:  J Exp Med       Date:  1965-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.